Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. (Q44082487)

29 November 2017

Entecavir and interferon-α sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. (English)

1 reference

29 November 2017

1 reference

1 reference

Masaru Enomoto

1

1 reference

29 November 2017

Shuhei Nishiguchi

2

1 reference

29 November 2017

Akihiro Tamori

3

1 reference

29 November 2017

Sawako Kobayashi

4

1 reference

29 November 2017

Hiroki Sakaguchi

5

1 reference

29 November 2017

Susumu Shiomi

6

1 reference

29 November 2017

Soo Ryang Kim

7

1 reference

29 November 2017

Hirayuki Enomoto

8

1 reference

29 November 2017

Masaki Saito

9

1 reference

29 November 2017

Hiroyasu Imanishi

10

1 reference

29 November 2017

Norifumi Kawada

11

1 reference

29 November 2017

language of work or name

1 reference

2 August 2012

1 reference

Journal of Gastroenterology

29 November 2017

1 reference

29 November 2017

48

1 reference

29 November 2017

3

1 reference

29 November 2017

397-404

1 reference

Hepatitis B Virus Infection

29 November 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Lamivudine and IFN-beta sequential therapy in HBe antigen-positive patients with chronic hepatitis B virus genotype C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Effect of nucleoside analog-interferon sequential therapy on patients with acute exacerbation of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Quantitative detection of hepatitis B surface antigen by chemiluminescent microparticle immunoassay during lamivudine treatment of chronic hepatitis B virus carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Hepatitis B virus immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0645-5

Management of HBV infection in Japan

21 January 2018

1 reference

12 December 2020

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B

1 reference

12 December 2020

Hepatitis B virus genotypes and response to antiviral therapy.

1 reference

12 December 2020

Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

12 December 2020

10.1007/S00535-012-0645-5

Identifiers

DOI

1 reference

29 November 2017

1 reference